CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Lopinavir/ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00084058
NCT00084058Phase 2Completed
CompareCT.gov

A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jun 7, 2004·Updated Nov 1, 2021

In Brief

A Phase 2 clinical trial evaluating Lopinavir/ritonavir and Saquinavir for HIV Infections. Completed, enrolled 26 participants across 15 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the effect of increased doses of lopinavir/ritonavir (LPV/r) and saquinavir (SQV) in HIV infected children who are failing their current antiretroviral regimen

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesPuerto Rico, United States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 7, 2004
Study CompletionDec 1, 2006
TodayJul 2, 2026
Posted 22.1 years ago

Interventions

Lopinavir/ritonavirdrug

Saquinavirdrug